Facile construction of gefitinib‐loaded zeolitic imidazolate framework nanocomposites for the treatment of different lung cancer cells
Biotechnology and Applied Biochemistry · 2024
DOI: 10.1002/bab.2585 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2024. Verfasst von Kalaivani Aiyasamy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vivekanandha College of Arts and Sciences for Women (Autonomous), Tiruchengode, Namakkal, Tamil Nadu, India. Hauptthemen laut MEDLINE: Lung Neoplasms, Zeolites, Antineoplastic Agents, Nanocomposites. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Gefitinib (GET) is a revolutionary targeted treatment inhibiting the epidermal growth factor receptor's tyrosine kinase action by competitively inhibiting the ATP binding site. In preclinical trials, several lung cancer cell lines and xenografts have demonstrated potential activity with GET. Response rates neared 25% in preclinical trials for non‐small cell lung cancer. Here, we describe the one‐pot synthesis of GET@ZIF‐8 nanocomposites (NCs) in pure water, encapsulating zeolitic imidazolate framework 8 (ZIF‐8). This method developed NCs with consistent morphology and a loading efficiency of 9%, resulting in a loading capacity of 20 wt%. Cell proliferation assay assessed the anticancer effect of GET@ZIF‐8 NCs on A549 and H1299 cells. The different biochemical staining (Calcein‐AM and PI and 4′,6‐Diamidino‐2‐phenylindole nuclear staining) assays assessed the cell death and morphological examination. Additionally, the mode of apoptosis was evaluated by mitochondrial membrane potential (∆ ψ m) and reactive oxygen species. Therefore, the study concludes that GET@ZIF‐8 NCs are pledged to treat lung cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Vivekanandha College of Arts and Sciences for Women (Autonomous), Tiruchengode, Namakkal, Tamil Nadu, India.
- Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
- Department of Chemistry, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India.
- Preclinical Department, Faculty of Medicine, Universiti Kuala Lumpur, Royal College of Medicine Perak (UniKL-RCMP), Perak, Malaysia.
- Guangdong Provincial Key Laboratory of Nanophotonic Functional Materials and Devices, School of Information and Optoelectronic Science and Engineering, South China Normal University, Guangzhou, China.
- Department of Chemistry, CHRIST (Deemed to be University), Bangalore, India.
ORCID-Profile: Indumathi Thangavelu
Zitieren
APA
Aiyasamy, K., Ramasamy, M., Hirad, A. H., Arulselvan, P., Jaganathan, R., Suriyaprakash, J., Thangavelu, I., & Alarfaj, A. A. (2024). Facile construction of gefitinib‐loaded zeolitic imidazolate framework nanocomposites for the treatment of different lung cancer cells. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2585
Vancouver
Aiyasamy K, Ramasamy M, Hirad AH, Arulselvan P, Jaganathan R, Suriyaprakash J, et al. Facile construction of gefitinib‐loaded zeolitic imidazolate framework nanocomposites for the treatment of different lung cancer cells. Biotechnology and Applied Biochemistry. 2024. doi:10.1002/bab.2585
BibTeX
@article{Aiyasamy2024,
author = {Aiyasamy, Kalaivani and Ramasamy, Malathi and Hirad, Abdurahman Hajinur and Arulselvan, Palanisamy and Jaganathan, Ravindran and Suriyaprakash, Jagadeesh and Thangavelu, Indumathi and Alarfaj, Abdullah A},
title = {Facile construction of gefitinib‐loaded zeolitic imidazolate framework nanocomposites for the treatment of different lung cancer cells},
journal = {Biotechnology and Applied Biochemistry},
year = {2024},
doi = {10.1002/bab.2585}
}
EUVIMED